Expands Commercial coverage to 92% of total commercial lives
SparingVision, will present pharmacology and safety data on its lead product SPVN06
Preclinical studies support further development of AU-011 for choroidal metastasis
A live webcast of the presentation will be available on Aura's “Investors & Media” page
Brings in-depth R&D expertise in oncology, including ADCs, targeted radiotherapies, immunooncology and small molecules.
International pivotal trial expedited to potentially revolutionize hemodialysis treatment with an immediate and durable solution
Phase I dose escalation of LAVA-051, a novel bispecific gamma delta T-cell engager
Decision from the first pre-specified futility analysis at 400 patients is expected in July
First quarter 2022 revenue of $4.1 million, a 43% increase over prior year
We are encouraged by this data and look forward to further support the ongoing development of a uPARAPtargeting ADC in order to improve the outcome of our patients
Subscribe to our weekly newsletter for the latest updates on life sciences investments.